Nexara Health — Health Canada Drug Establishment Licence #3-002896

Trial comparator supply from Canada

Every trial below uses at least one comparator that is marketed in Canada, which means the comparator can be supplied with the Canadian label, Certificate of Analysis, batch number and expiry documentation, without a Special Access request. Nexara Health supplies comparator, rescue and ancillary medication to sponsors and CROs under Health Canada Drug Establishment Licence #3-002896 from Winnipeg, Manitoba.

Comparator supply fails for predictable reasons: the presentation available locally does not match the protocol, the shortage hits mid-study, or the source market cannot document the chain of custody an auditor expects. Sourcing the comparator from Canada solves the first two and documents the third. The list below is refreshed from the public trial registry; each page shows the marketed Canadian products, the manufacturers behind them, and the strengths that can be supplied.

NCTTrialComparatorSponsorStatusUpdated
NCT07426757An Open-Label Study to Evaluate PF-07994525 in Participants With Advanced CancersmidazolamPfizerRecruiting2026-09-04
NCT06377852The CDK4/6 Inhibitor Dosing Knowledge (CDK) StudyribociclibAmerican Society of Clinical OncologyRecruiting2026-09-04
NCT06172296Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed isotretinoinNational Cancer Institute (NCI)Recruiting2026-09-04
NCT07420283A Study of Brenipatide in Participants With Opioid Use DisorderbuprenorphineEli Lilly and CompanyRecruiting2026-09-04
NCT04655755Venetoclax in Combination With ASTX727 for the Treatment of Treatment-Naive High-Risk Myelodysplastic Syndrome or ChronivenetoclaxM.D. Anderson Cancer CenterActive Not Recruiting2026-09-04
NCT06377852The CDK4/6 Inhibitor Dosing Knowledge (CDK) Studypalbociclib 125mgAmerican Society of Clinical OncologyRecruiting2026-09-04
NCT05198830Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carbocarboplatin hexalNational Cancer Institute (NCI)Active Not Recruiting2026-09-04
NCT06172296Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed irinotecanNational Cancer Institute (NCI)Recruiting2026-09-04
NCT06937099Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and ObtirzepatideEli Lilly and CompanyRecruiting2026-09-04
NCT07416604A Clinical Study to Evaluate the Effects of NXT007 Compared to Emicizumab Prophylaxis in People With Hemophilia AemicizumabHoffmann-La RocheRecruiting2026-09-04
NCT01711554Lenalidomide and Dinutuximab With or Without Isotretinoin in Treating Younger Patients With Refractory or Recurrent NeurisotretinoinNational Cancer Institute (NCI)Active Not Recruiting2026-09-04
NCT04655755Venetoclax in Combination With ASTX727 for the Treatment of Treatment-Naive High-Risk Myelodysplastic Syndrome or Chronidecitabine and cedazuridineM.D. Anderson Cancer CenterActive Not Recruiting2026-09-04
NCT06124157A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolecyclophosphamide monohydrateNational Cancer Institute (NCI)Recruiting2026-09-04
NCT06377852The CDK4/6 Inhibitor Dosing Knowledge (CDK) StudypalbociclibAmerican Society of Clinical OncologyRecruiting2026-09-04
NCT07805655Radiofrequency Treatment Versus Topical Therapy for Facial Acne Vulgarisadapalene 0.1% and benzoyl peroxide 2.5% gelJeisys Medical IncRecruiting2026-09-04
NCT05198830Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or CarbocarboplatinNational Cancer Institute (NCI)Active Not Recruiting2026-09-04
NCT06096844Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, ThecarboplatinNational Cancer Institute (NCI)Recruiting2026-09-04
NCT06172296Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed etoposideNational Cancer Institute (NCI)Recruiting2026-09-04
NCT06400472A Study of Sofe-M in Participants With Selected Advanced Solid TumorspembrolizumabEli Lilly and CompanyRecruiting2026-09-04
NCT06937099Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and ObmirikizumabEli Lilly and CompanyRecruiting2026-09-04
NCT07198074Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With carboplatin hexalNational Cancer Institute (NCI)Recruiting2026-09-04
NCT07368998To Study the Effect of Inavolisib in Combination With Fulvestrant in Participants With Breast CancerinavolisibHoffmann-La RocheRecruiting2026-09-04
NCT07775313Base-Edited Hematopoietic Stem/Progenitor Cell Gene Therapy for Treatment of CXCR4-WHIMbusulfanNational Institute of Allergy and Infectious Diseases (NIAIDNot Yet Recruiting2026-09-04
NCT01366144Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed bpaclitaxelNational Cancer Institute (NCI)Active Not Recruiting2026-09-04
NCT03964090Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, and Rituximab (TEDDI-R) in Aggressive B-cell Lymphomas With SeibrutinibNational Cancer Institute (NCI)Active Not Recruiting2026-09-04
NCT04609046Testing the Addition of Lenalidomide and Nivolumab to the Usual Treatment for Primary CNS Lymphomamethotrexate methylaminopterinNational Cancer Institute (NCI)Active Not Recruiting2026-09-04
NCT05827081Phase IIIb Study of Ribociclib + ET in Early Breast CancerribociclibNovartis PharmaceuticalsRecruiting2026-09-04
NCT06124157A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, AdolecyclophosphamideNational Cancer Institute (NCI)Recruiting2026-09-04
NCT06124157A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, AdoleprednisoneNational Cancer Institute (NCI)Recruiting2026-09-04
NCT06369259Open-label Phase 2 Study of Avutometinib (RAF/MEK Clamp) in Combination With Defactinib (FAK Inhibitor) and Cetuximab incetuximabM.D. Anderson Cancer CenterRecruiting2026-09-04
NCT07604571Study of IEV407 as Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast CancerfulvestrantNovartis PharmaceuticalsRecruiting2026-09-04
NCT07804901Asciminib Frontline Risk Adapteddasatinib 80mg qdProf. Dr. med. Andreas HochhausNot Yet Recruiting2026-09-04
NCT04391049Testing the Addition of the Anti-cancer Viral Therapy Telomelysin™ to Chemoradiation for Patients With Advanced EsophagepaclitaxelNRG OncologyActive Not Recruiting2026-09-04
NCT05192798Albumin-Bound Paclitaxel Combined With Antiangiogenic Agents in First-line Treatment of Relapsed or Metastatic TNBCbevacizumabThe First Affiliated Hospital of Bengbu Medical UniversityRecruiting2026-09-04
NCT05675410A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumabvinblastine sulfateNational Cancer Institute (NCI)Recruiting2026-09-04
NCT06043323A Phase II Study of Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor (CAR) Tcell Therapy, in Combination prednisoneM.D. Anderson Cancer CenterRecruiting2026-09-04
NCT06096844Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, ThepemetrexedNational Cancer Institute (NCI)Recruiting2026-09-04
NCT06172296Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed doxorubicinNational Cancer Institute (NCI)Recruiting2026-09-04
NCT06191978A Phase Ia/Ib Open-label, Multiple Dose, Study to Determine the Recommended Dose, Evaluate PKs, PDs, Safety, and ActivitvenetoclaxM.D. Anderson Cancer CenterRecruiting2026-09-04
NCT06400472A Study of Sofe-M in Participants With Selected Advanced Solid TumorsitraconazoleEli Lilly and CompanyRecruiting2026-09-04
NCT06712316Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for LpembrolizumabBioNTech SERecruiting2026-09-04
NCT06930651A Phase I/II Study of CAR.70-Engineered IL15-Transduced Cord Blood-Derived NK Cells With TGF-beta Receptor 2 (TGFBR2) KnfludarabineM.D. Anderson Cancer CenterRecruiting2026-09-04
NCT07061977Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance CcarboplatinNational Cancer Institute (NCI)Recruiting2026-09-04
NCT07198074Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With carboplatinNational Cancer Institute (NCI)Recruiting2026-09-04
NCT07281417Testing the Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment Given Prior to Surgery in Patients With Sinonasacarboplatin hexalNational Cancer Institute (NCI)Recruiting2026-09-04
NCT07368998To Study the Effect of Inavolisib in Combination With Fulvestrant in Participants With Breast CancerfulvestrantHoffmann-La RocheRecruiting2026-09-04
NCT07661979Opzelura Experience StudyruxolitinibWake Forest University Health SciencesNot Yet Recruiting2026-09-04
NCT07767175A First-in-human Research Study on How NNC0721-8060 Works in People Living With Overweight or ObesitysemaglutideNovo Nordisk A/SRecruiting2026-09-04
NCT07805135A Study of HB1801 Versus Docetaxel (Taxotere®) in Patients With Advanced Breast CancerdocetaxelCSPC ZhongQi Pharmaceutical Technology Co., Ltd.Not Yet Recruiting2026-09-04
NCT01366144Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed bcarboplatin hexalNational Cancer Institute (NCI)Active Not Recruiting2026-09-04
NCT01949129Allogeneic Stem Cell Transplantation for Children and Adolescents With Acute Lymphoblastic LeukaemiatreosulfanSt. Anna KinderkrebsforschungRecruiting2026-09-04
NCT03964090Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, and Rituximab (TEDDI-R) in Aggressive B-cell Lymphomas With SecytarabineNational Cancer Institute (NCI)Active Not Recruiting2026-09-04
NCT04267848Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung carboplatin hexalNational Cancer Institute (NCI)Recruiting2026-09-04
NCT04609046Testing the Addition of Lenalidomide and Nivolumab to the Usual Treatment for Primary CNS Lymphomamethotrexate lpfNational Cancer Institute (NCI)Active Not Recruiting2026-09-04
NCT05652478Early Metabolic Effects of Antiretroviral Drugs in Healthy volUnteers: a Phase 2 Randomized StudydolutegravirNational Institute of Allergy and Infectious Diseases (NIAIDRecruiting2026-09-04
NCT05827081Phase IIIb Study of Ribociclib + ET in Early Breast CancerleuprolideNovartis PharmaceuticalsRecruiting2026-09-04
NCT06058377Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, doxorubicinNational Cancer Institute (NCI)Recruiting2026-09-04
NCT06124157A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolecalaspargase pegolNational Cancer Institute (NCI)Recruiting2026-09-04
NCT06124157A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, AdoleimatinibNational Cancer Institute (NCI)Recruiting2026-09-04
NCT06124157A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, AdoleprednisoloneNational Cancer Institute (NCI)Recruiting2026-09-04
NCT06132113DAREON™-7: A Study to Test How Well Different Doses of BI 764532 in Addition to Chemotherapy Are Tolerated by People WitcisplatinBoehringer IngelheimActive Not Recruiting2026-09-04
NCT06311214Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatienfortumab vedotinNational Cancer Institute (NCI)Recruiting2026-09-04
NCT07524530Stem Cell Transplantation for Participants With Germline RUNX1 Associated Blood CancerscyclophosphamideNational Cancer Institute (NCI)Not Yet Recruiting2026-09-04
NCT07599176Partial Stem Cell Transplant for Sickle Cell Disease From Matched DonorsalemtuzumabNational Heart, Lung, and Blood Institute (NHLBI)Recruiting2026-09-04
NCT07756840Combination Bevacizumab and PRGN-2012 in Adults With Recurrent Respiratory Papillomatosis (RRP)bevacizumabNational Cancer Institute (NCI)Not Yet Recruiting2026-09-04
NCT07804381Disease-modifying Efficacy of Sitagliptin Therapy in Early-stage Parkinson's DiseasesitagliptinYonsei UniversityNot Yet Recruiting2026-09-04
NCT02559778Pediatric Precision Laboratory Advanced Neuroblastoma TherapyvorinostatGiselle ShollerRecruiting2026-09-04
NCT04391049Testing the Addition of the Anti-cancer Viral Therapy Telomelysin™ to Chemoradiation for Patients With Advanced Esophagecarboplatin hexalNRG OncologyActive Not Recruiting2026-09-04
NCT04680052A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus LelenalidomideIncyte CorporationActive Not Recruiting2026-09-04
NCT04992624Cannabinoid Interactions With Central and Peripheral Pain Mechanisms in Osteoarthritis of the KneecannabidiolSteven E Harte, PhDRecruiting2026-09-04
NCT05675410A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and NivolumabdacarbazineNational Cancer Institute (NCI)Recruiting2026-09-04
NCT05675410A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumabprednisone intensolNational Cancer Institute (NCI)Recruiting2026-09-04
NCT06043323A Phase II Study of Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor (CAR) Tcell Therapy, in Combination acetaminophenM.D. Anderson Cancer CenterRecruiting2026-09-04
NCT06043323A Phase II Study of Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor (CAR) Tcell Therapy, in Combination fludarabine phosphateM.D. Anderson Cancer CenterRecruiting2026-09-04
NCT06096844Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, Thepaclitaxel albuminNational Cancer Institute (NCI)Recruiting2026-09-04
NCT06096844Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, Thepaclitaxel protein-boundNational Cancer Institute (NCI)Recruiting2026-09-04
NCT06172296Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed carboplatin hexalNational Cancer Institute (NCI)Recruiting2026-09-04
NCT06172296Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed cyclophosphamide monohydrateNational Cancer Institute (NCI)Recruiting2026-09-04
NCT06172296Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed temozolomideNational Cancer Institute (NCI)Recruiting2026-09-04
NCT06172296Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed vincristineNational Cancer Institute (NCI)Recruiting2026-09-04
NCT06321302A Study to Test Whether BI 764524 Helps People With an Eye Condition Called Diabetic Retinopathyaflibercept (eylea®) - us onlyBoehringer IngelheimActive Not Recruiting2026-09-04
NCT06400472A Study of Sofe-M in Participants With Selected Advanced Solid TumorscarboplatinEli Lilly and CompanyRecruiting2026-09-04
NCT06439277A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)tirzepatideEli Lilly and CompanyRecruiting2026-09-04
NCT06712316Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for LpaclitaxelBioNTech SERecruiting2026-09-04
NCT06807281A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe EczemaabrocitinibPfizerRecruiting2026-09-04
NCT06930651A Phase I/II Study of CAR.70-Engineered IL15-Transduced Cord Blood-Derived NK Cells With TGF-beta Receptor 2 (TGFBR2) KndexamethasoneM.D. Anderson Cancer CenterRecruiting2026-09-04
NCT06973811ZR-MTX for PIOL Phase II TrialrituximabPeking Union Medical College HospitalRecruiting2026-09-04
NCT07059091Clinical Trial of Omalizumab for Allergen Sensitized and Exposed Individuals With COPDsodium chloride (nacl) 0.9 %Johns Hopkins UniversityRecruiting2026-09-04
NCT07061977Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance CpaclitaxelNational Cancer Institute (NCI)Recruiting2026-09-04
NCT07188896A Randomized Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal nivolumabBrian RiniRecruiting2026-09-04
NCT07222137A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and AdultsbaricitinibEli Lilly and CompanyRecruiting2026-09-04
NCT07281417Testing the Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment Given Prior to Surgery in Patients With SinonasacarboplatinNational Cancer Institute (NCI)Recruiting2026-09-04
NCT07287917Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid TumorscapivasertibAminex Therapeutics, Inc.Recruiting2026-09-04
NCT07291037Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic NdocetaxelAstraZenecaRecruiting2026-09-04
NCT07479797Study Evaluating the Efficacy of KITE-753 Versus Axicabtagene Ciloleucel in Participants With Relapsed or Refractory LarcyclophosphamideKite, A Gilead CompanyRecruiting2026-09-04
NCT07640932Lurbinectedin Plus Paclitaxel Versus Paclitaxel in Patients With Previously Treated Small Cell Lung CancerpaclitaxelYonsei UniversityNot Yet Recruiting2026-09-04
NCT07672483IL-12 Genetically Engineered Myeloid Cells in Participants With Relapsed, Refractory Solid TumorscetuximabNational Cancer Institute (NCI)Not Yet Recruiting2026-09-04
NCT07715903Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic ArtcarfilzomibNational Cancer Institute (NCI)Not Yet Recruiting2026-09-04
NCT07803744A Study of Tirzepatide (LY3298176) in Participants With Type 1 Diabetes Mellitus and Overweight or ObesityacetaminophenEli Lilly and CompanyNot Yet Recruiting2026-09-04
NCT07803978Prospective Randomized Controlled Study: Amimaitosai Injection Combined With Corticosteroids for Gastrointestinal aGVHDmethylprednisoloneChinese PLA General HospitalEnrolling By Invitation2026-09-04
NCT07805551A Study of HDM2017 Combination Therapy in Advanced Colorectal CancerfluorouracilHangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.Recruiting2026-09-04
NCT07775313Base-Edited Hematopoietic Stem/Progenitor Cell Gene Therapy for Treatment of CXCR4-WHIMfilgrastimNational Institute of Allergy and Infectious Diseases (NIAIDNot Yet Recruiting2026-09-04
NCT01949129Allogeneic Stem Cell Transplantation for Children and Adolescents With Acute Lymphoblastic LeukaemiacyclophosphamideSt. Anna KinderkrebsforschungRecruiting2026-09-04
NCT01949129Allogeneic Stem Cell Transplantation for Children and Adolescents With Acute Lymphoblastic LeukaemiathiotepaSt. Anna KinderkrebsforschungRecruiting2026-09-04
NCT02981940A Study of Abemaciclib in Recurrent GlioblastomaabemaciclibDana-Farber Cancer InstituteActive Not Recruiting2026-09-04
NCT03383575Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic SyndromeazacitidineM.D. Anderson Cancer CenterRecruiting2026-09-04
NCT04005690Targeted Pathway Inhibition in Patients With Pancreatic CancercobimetinibOHSU Knight Cancer InstituteRecruiting2026-09-04
NCT04267848Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung carboplatinNational Cancer Institute (NCI)Recruiting2026-09-04
NCT04269902Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLvenetoclaxNational Cancer Institute (NCI)Recruiting2026-09-04
NCT04609046Testing the Addition of Lenalidomide and Nivolumab to the Usual Treatment for Primary CNS LymphomamethotrexateNational Cancer Institute (NCI)Active Not Recruiting2026-09-04
NCT05010122ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutated Acute MygilteritinibM.D. Anderson Cancer CenterRecruiting2026-09-04
NCT05271409A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With MysatralizumabHoffmann-La RocheActive Not Recruiting2026-09-04
NCT05711615Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advdoxorubicin hydrochloride liposomeNational Cancer Institute (NCI)Recruiting2026-09-04
NCT05827081Phase IIIb Study of Ribociclib + ET in Early Breast CancerletrozoleNovartis PharmaceuticalsRecruiting2026-09-04
NCT05849662A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic LeukemiafludarabineTherapeutic Advances in Childhood Leukemia ConsortiumRecruiting2026-09-04
NCT06058377Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, cyclophosphamide monohydrateNational Cancer Institute (NCI)Recruiting2026-09-04
NCT06064097A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC)gemcitabineNational Cancer Institute (NCI)Recruiting2026-09-04
NCT06077500DAREONᵀᴹ-8: A Study to Test How Well Different Doses of BI 764532 in Addition to Standard of Care Are Tolerated by PeopletoposideBoehringer IngelheimActive Not Recruiting2026-09-04
NCT06124157A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adoledasatinib hydrateNational Cancer Institute (NCI)Recruiting2026-09-04
NCT06124157A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, AdoledoxorubicinNational Cancer Institute (NCI)Recruiting2026-09-04
NCT06124157A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, AdolemethotrexateNational Cancer Institute (NCI)Recruiting2026-09-04
NCT06124157A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, AdolepegaspargaseNational Cancer Institute (NCI)Recruiting2026-09-04
NCT06124157A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolethioguanine hemihydrateNational Cancer Institute (NCI)Recruiting2026-09-04
NCT06132113DAREON™-7: A Study to Test How Well Different Doses of BI 764532 in Addition to Chemotherapy Are Tolerated by People WitcarboplatinBoehringer IngelheimActive Not Recruiting2026-09-04
NCT06236438Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With BcarboplatinAbbVieRecruiting2026-09-04
NCT06236438Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With BpemetrexedAbbVieRecruiting2026-09-04
NCT07509034Autologous B7-H3 Chimeric Antigen Receptor T Cells in Previously Treated Extensive-Stage Small Cell Lung Cancer With RecfludarabineNational Cancer Institute (NCI)Not Yet Recruiting2026-09-04
NCT07524530Stem Cell Transplantation for Participants With Germline RUNX1 Associated Blood CancersbusulfanNational Cancer Institute (NCI)Not Yet Recruiting2026-09-04
NCT07524530Stem Cell Transplantation for Participants With Germline RUNX1 Associated Blood CancerstacrolimusNational Cancer Institute (NCI)Not Yet Recruiting2026-09-04
NCT07599176Partial Stem Cell Transplant for Sickle Cell Disease From Matched DonorsabataceptNational Heart, Lung, and Blood Institute (NHLBI)Recruiting2026-09-04
NCT01695941Alisertib, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or B-cell LowbortezomibNational Cancer Institute (NCI)Active Not Recruiting2026-09-04
NCT07638527Time to First Rescue Antiemetic With Ondansetron Plus Metoclopramide Versus Dexamethasone Plus Metoclopramide for PONV Pondansetron 4 mgFaisalabad Medical UniversityRecruiting2026-09-04
NCT07803653IL-18 Armored STEAP1 CAR T Cells for the Treatment of Metastatic Castration Resistant Prostate CancerfludarabineFred Hutchinson Cancer CenterNot Yet Recruiting2026-09-04
NCT07804199taVNS in Veterans With Knee OA (AVAHCS)methylprednisolone acetateVA Office of Research and DevelopmentNot Yet Recruiting2026-09-04
NCT02208375mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and OvarianolaparibM.D. Anderson Cancer CenterActive Not Recruiting2026-09-04
NCT02559778Pediatric Precision Laboratory Advanced Neuroblastoma TherapysorafenibGiselle ShollerRecruiting2026-09-04
NCT04340141Testing the Use of the Usual Chemotherapy Before and After Surgery for Removable Pancreatic CancerfluorouracilAlliance for Clinical Trials in OncologyActive Not Recruiting2026-09-04
NCT04391049Testing the Addition of the Anti-cancer Viral Therapy Telomelysin™ to Chemoradiation for Patients With Advanced EsophagecarboplatinNRG OncologyActive Not Recruiting2026-09-04
NCT04589845Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform StudyentrectinibHoffmann-La RocheActive Not Recruiting2026-09-04
NCT04597359To Evaluate if Green Tea Can be Effective in Reducing the Progression of Prostate Cancer in Men on Close MonitoringsinecatechinsECOG-ACRIN Cancer Research GroupActive Not Recruiting2026-09-04
NCT04746235Venetoclax and ASTX727 for the Treatment of Relapsed, Refractory, or Newly Diagnosed Acute Myeloid Leukemiadecitabine and cedazuridineM.D. Anderson Cancer CenterActive Not Recruiting2026-09-04
NCT04858334APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in PatientolaparibNational Cancer Institute (NCI)Recruiting2026-09-04
NCT05315700Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alterationcarboplatin and pemetrexedORIC PharmaceuticalsRecruiting2026-09-04
NCT05675410A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumabcyclophosphamide monohydrateNational Cancer Institute (NCI)Recruiting2026-09-04
NCT05675410A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and NivolumabetoposideNational Cancer Institute (NCI)Recruiting2026-09-04
NCT05675410A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and NivolumabprednisoneNational Cancer Institute (NCI)Recruiting2026-09-04
NCT05751512A Study to Evaluate MRG003 vs Cetuximab/Methotrexate in in the Treatment of Patients With RM-SCCHNcetuximab injectionLepu Biopharma Co., Ltd.Recruiting2026-09-04
NCT05952024Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCLacalabrutinibAstraZenecaRecruiting2026-09-04
NCT06043323A Phase II Study of Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor (CAR) Tcell Therapy, in Combination cyclophosphamideM.D. Anderson Cancer CenterRecruiting2026-09-04
NCT06043323A Phase II Study of Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor (CAR) Tcell Therapy, in Combination diphenhydramineM.D. Anderson Cancer CenterRecruiting2026-09-04
NCT06096844Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, Thecarboplatin hexalNational Cancer Institute (NCI)Recruiting2026-09-04
NCT06096844Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, ThepaclitaxelNational Cancer Institute (NCI)Recruiting2026-09-04
NCT06096844Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, Thepaclitaxel albumin-stabilized nanoparticle formulationNational Cancer Institute (NCI)Recruiting2026-09-04
NCT06096844Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, Thepaclitaxel nanoparticle albumin-boundNational Cancer Institute (NCI)Recruiting2026-09-04
NCT06126276Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (palbociclibNational Cancer Institute (NCI)Recruiting2026-09-04
NCT06172296Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed carboplatinNational Cancer Institute (NCI)Recruiting2026-09-04
NCT06172296Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed cisplatinNational Cancer Institute (NCI)Recruiting2026-09-04
NCT06172296Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed cyclophosphamideNational Cancer Institute (NCI)Recruiting2026-09-04
NCT06172296Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed melphalanNational Cancer Institute (NCI)Recruiting2026-09-04
NCT06172296Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed melphalan for injection-hepatic delivery systemNational Cancer Institute (NCI)Recruiting2026-09-04
NCT06172296Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed thiotepaNational Cancer Institute (NCI)Recruiting2026-09-04
NCT06172296Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed topotecanNational Cancer Institute (NCI)Recruiting2026-09-04
NCT06247995A Phase I/II, Dose Finding and Optimization Study of [177Lu]Lu-NeoB in Combination With Capecitabine in Patients With GRcapecitabineNovartis PharmaceuticalsActive Not Recruiting2026-09-04
NCT06298084Dose-Expansion Modular Study To Explore the Safety, Tolerability, and Anti-tumor Activity of HER3- DXd Monotherapy and ColaparibGustave Roussy, Cancer Campus, Grand ParisRecruiting2026-09-04
NCT06355414Psilocybin in Chronic Low Back Pain and DepressionmethylphenidateJohns Hopkins UniversityRecruiting2026-09-04
NCT06400472A Study of Sofe-M in Participants With Selected Advanced Solid TumorsbevacizumabEli Lilly and CompanyRecruiting2026-09-04
NCT06406465A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and ToxicitycisplatinNational Cancer Institute (NCI)Recruiting2026-09-04
NCT06406465A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and ToxicityetoposideNational Cancer Institute (NCI)Recruiting2026-09-04
NCT07188896A Randomized Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal cemiplimabBrian RiniRecruiting2026-09-04
NCT06712316Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for LcarboplatinBioNTech SERecruiting2026-09-04
NCT06712316Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for LpemetrexedBioNTech SERecruiting2026-09-04
NCT06806293Study of Oral Atogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual MigatogepantAbbVieActive Not Recruiting2026-09-04
NCT06930651A Phase I/II Study of CAR.70-Engineered IL15-Transduced Cord Blood-Derived NK Cells With TGF-beta Receptor 2 (TGFBR2) KncyclophosphamideM.D. Anderson Cancer CenterRecruiting2026-09-04
NCT06930651A Phase I/II Study of CAR.70-Engineered IL15-Transduced Cord Blood-Derived NK Cells With TGF-beta Receptor 2 (TGFBR2) KndecitabineM.D. Anderson Cancer CenterRecruiting2026-09-04
NCT06948097Syk Inhibition in MItigating Lung Allograft Rejection (SIMILAR): A Trial to Evaluate the Safety and Tolerability of FostfostamatinibNational Heart, Lung, and Blood Institute (NHLBI)Recruiting2026-09-04
NCT06973811ZR-MTX for PIOL Phase II TrialmethotrexatePeking Union Medical College HospitalRecruiting2026-09-04
NCT06973811ZR-MTX for PIOL Phase II TrialzanubrutinibPeking Union Medical College HospitalRecruiting2026-09-04
NCT07059091Clinical Trial of Omalizumab for Allergen Sensitized and Exposed Individuals With COPDomalizumabJohns Hopkins UniversityRecruiting2026-09-04
NCT07061977Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Ccarboplatin hexalNational Cancer Institute (NCI)Recruiting2026-09-04
NCT07061977Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance CcisplatinNational Cancer Institute (NCI)Recruiting2026-09-04
NCT07144111A Study to Evaluate the Effect of Moderate or Severe Hepatic Impairment on the Pharmacokinetics (PK) of InavolisibinavolisibGenentech, Inc.Recruiting2026-09-04
NCT07188896A Randomized Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal ipilimumabBrian RiniRecruiting2026-09-04
NCT07198074Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With paclitaxelNational Cancer Institute (NCI)Recruiting2026-09-04
NCT07218341A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaidelalisibEli Lilly and CompanyRecruiting2026-09-04
NCT07222332A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 DiabaricitinibEli Lilly and CompanyRecruiting2026-09-04
NCT07262983Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or AtopibaricitinibNational Institute of Allergy and Infectious Diseases (NIAIDRecruiting2026-09-04
NCT07281417Testing the Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment Given Prior to Surgery in Patients With SinonasacisplatinNational Cancer Institute (NCI)Recruiting2026-09-04
NCT07281417Testing the Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment Given Prior to Surgery in Patients With SinonasapaclitaxelNational Cancer Institute (NCI)Recruiting2026-09-04
NCT07287917Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid TumorsfulvestrantAminex Therapeutics, Inc.Recruiting2026-09-04
NCT07287917Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid TumorspembrolizumabAminex Therapeutics, Inc.Recruiting2026-09-04
NCT07468071Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single AgentrametinibNovartis PharmaceuticalsRecruiting2026-09-04
NCT07479797Study Evaluating the Efficacy of KITE-753 Versus Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Laraxicabtagene ciloleucelKite, A Gilead CompanyRecruiting2026-09-04
NCT07637578A Study of Elranatamab Outpatient Administration in Patients With Relapsed/Refractory Multiple MyelomatocilizumabSCRI Development Innovations, LLCRecruiting2026-09-04
NCT07640932Lurbinectedin Plus Paclitaxel Versus Paclitaxel in Patients With Previously Treated Small Cell Lung CancerlurbinectedinYonsei UniversityNot Yet Recruiting2026-09-04
NCT07667335Enfortumab Vedotin, Pembrolizumab and Quemliclustat for the Treatment of Unresectable Locally Advanced and Metastatic Urenfortumab vedotinFred Hutchinson Cancer CenterNot Yet Recruiting2026-09-04
NCT07669207Extended Azithromycin Treatment in Prelabor Rupture of MembranesazithromycinAlexa HendersonRecruiting2026-09-04
NCT07672483IL-12 Genetically Engineered Myeloid Cells in Participants With Relapsed, Refractory Solid TumorscyclophosphamideNational Cancer Institute (NCI)Not Yet Recruiting2026-09-04
NCT07672483IL-12 Genetically Engineered Myeloid Cells in Participants With Relapsed, Refractory Solid TumorsfludarabineNational Cancer Institute (NCI)Not Yet Recruiting2026-09-04
NCT01366144Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed bcarboplatinNational Cancer Institute (NCI)Active Not Recruiting2026-09-04
NCT07775313Base-Edited Hematopoietic Stem/Progenitor Cell Gene Therapy for Treatment of CXCR4-WHIMplerixaforNational Institute of Allergy and Infectious Diseases (NIAIDNot Yet Recruiting2026-09-04
NCT07803744A Study of Tirzepatide (LY3298176) in Participants With Type 1 Diabetes Mellitus and Overweight or ObesitytirzepatideEli Lilly and CompanyNot Yet Recruiting2026-09-04
NCT07803848Study to Confirm Efficacy and Feasibility of Tarlatamab Treatment in Patients With Extensive Stage Small-cell Lung CancetarlatamabAIO-Studien-gGmbHRecruiting2026-09-04
NCT07805551A Study of HDM2017 Combination Therapy in Advanced Colorectal CancerbevacizumabHangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.Recruiting2026-09-04
NCT07805551A Study of HDM2017 Combination Therapy in Advanced Colorectal CancercapecitabineHangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.Recruiting2026-09-04
NCT07805551A Study of HDM2017 Combination Therapy in Advanced Colorectal CancerleucovorinHangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.Recruiting2026-09-04
NCT07805551A Study of HDM2017 Combination Therapy in Advanced Colorectal CanceroxaliplatinHangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.Recruiting2026-09-04
NCT01711554Lenalidomide and Dinutuximab With or Without Isotretinoin in Treating Younger Patients With Refractory or Recurrent NeurlenalidomideNational Cancer Institute (NCI)Active Not Recruiting2026-09-04
NCT01949129Allogeneic Stem Cell Transplantation for Children and Adolescents With Acute Lymphoblastic LeukaemiabusulfanSt. Anna KinderkrebsforschungRecruiting2026-09-04
NCT01949129Allogeneic Stem Cell Transplantation for Children and Adolescents With Acute Lymphoblastic LeukaemiaetoposideSt. Anna KinderkrebsforschungRecruiting2026-09-04
NCT01949129Allogeneic Stem Cell Transplantation for Children and Adolescents With Acute Lymphoblastic LeukaemiafludarabineSt. Anna KinderkrebsforschungRecruiting2026-09-04
NCT02642042Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung CancdocetaxelNational Cancer Institute (NCI)Active Not Recruiting2026-09-04
NCT02642042Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung CanctrametinibNational Cancer Institute (NCI)Active Not Recruiting2026-09-04
NCT03340506Dabrafenib and/or Trametinib Rollover StudydabrafenibNovartis PharmaceuticalsRecruiting2026-09-04
NCT03340506Dabrafenib and/or Trametinib Rollover StudytrametinibNovartis PharmaceuticalsRecruiting2026-09-04
NCT03964090Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, and Rituximab (TEDDI-R) in Aggressive B-cell Lymphomas With SeisavuconazoleNational Cancer Institute (NCI)Active Not Recruiting2026-09-04
NCT03964090Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, and Rituximab (TEDDI-R) in Aggressive B-cell Lymphomas With SemethotrexateNational Cancer Institute (NCI)Active Not Recruiting2026-09-04
NCT04005690Targeted Pathway Inhibition in Patients With Pancreatic CancerolaparibOHSU Knight Cancer InstituteRecruiting2026-09-04
NCT04176172Optimizing Tobacco Use Treatment for PLWHAvareniclineAbramson Cancer Center at Penn MedicineActive Not Recruiting2026-09-04
NCT04267848Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung cisplatinNational Cancer Institute (NCI)Recruiting2026-09-04
NCT04267848Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung paclitaxelNational Cancer Institute (NCI)Recruiting2026-09-04
NCT04447911Effects of the SGLT2 Inhibitor Empagliflozin in Patients With Euvolemic and Hypervolemic Hyponatremiaempagliflozin 25 mgUniversity Hospital, Basel, SwitzerlandRecruiting2026-09-04
NCT04609046Testing the Addition of Lenalidomide and Nivolumab to the Usual Treatment for Primary CNS LymphomalenalidomideNational Cancer Institute (NCI)Active Not Recruiting2026-09-04
NCT04760717Regulating Blood Pressure During Recovery From Intracerebral Hemorrhage and Ischemic Strokespironolactone pillYale UniversityActive Not Recruiting2026-09-04
NCT05010122ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutated Acute Mydecitabine and cedazuridineM.D. Anderson Cancer CenterRecruiting2026-09-04
NCT05010122ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutated Acute MyvenetoclaxM.D. Anderson Cancer CenterRecruiting2026-09-04
NCT05099003A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) GselinexorNational Cancer Institute (NCI)Recruiting2026-09-04
NCT05652478Early Metabolic Effects of Antiretroviral Drugs in Healthy volUnteers: a Phase 2 Randomized Studytenofovir alafenamideNational Institute of Allergy and Infectious Diseases (NIAIDRecruiting2026-09-04
NCT05652478Early Metabolic Effects of Antiretroviral Drugs in Healthy volUnteers: a Phase 2 Randomized Studytenofovir disoproxil fumarateNational Institute of Allergy and Infectious Diseases (NIAIDRecruiting2026-09-04
NCT05827081Phase IIIb Study of Ribociclib + ET in Early Breast CancerexemestaneNovartis PharmaceuticalsRecruiting2026-09-04
NCT05827081Phase IIIb Study of Ribociclib + ET in Early Breast CancergoserelinNovartis PharmaceuticalsRecruiting2026-09-04
NCT05849662A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic LeukemiaazacitidineTherapeutic Advances in Childhood Leukemia ConsortiumRecruiting2026-09-04
NCT05849662A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic LeukemiacytarabineTherapeutic Advances in Childhood Leukemia ConsortiumRecruiting2026-09-04
NCT05849662A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic LeukemiatrametinibTherapeutic Advances in Childhood Leukemia ConsortiumRecruiting2026-09-04
NCT06058377Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, cyclophosphamideNational Cancer Institute (NCI)Recruiting2026-09-04
NCT06058377Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, paclitaxelNational Cancer Institute (NCI)Recruiting2026-09-04
NCT06064097A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC)cisplatinNational Cancer Institute (NCI)Recruiting2026-09-04
NCT06077500DAREONᵀᴹ-8: A Study to Test How Well Different Doses of BI 764532 in Addition to Standard of Care Are Tolerated by PeoplatezolizumabBoehringer IngelheimActive Not Recruiting2026-09-04
NCT06077500DAREONᵀᴹ-8: A Study to Test How Well Different Doses of BI 764532 in Addition to Standard of Care Are Tolerated by PeoplcarboplatinBoehringer IngelheimActive Not Recruiting2026-09-04
NCT06124157A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, AdolecytarabineNational Cancer Institute (NCI)Recruiting2026-09-04
NCT06124157A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, AdoledasatinibNational Cancer Institute (NCI)Recruiting2026-09-04
NCT06124157A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adoledasatinib monohydrateNational Cancer Institute (NCI)Recruiting2026-09-04
NCT06124157A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, AdoledaunorubicinNational Cancer Institute (NCI)Recruiting2026-09-04
NCT06124157A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, AdoleleucovorinNational Cancer Institute (NCI)Recruiting2026-09-04
NCT06124157A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, AdolemercaptopurineNational Cancer Institute (NCI)Recruiting2026-09-04
NCT06124157A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolemethotrexate lpfNational Cancer Institute (NCI)Recruiting2026-09-04
NCT06124157A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolemethotrexate methylaminopterinNational Cancer Institute (NCI)Recruiting2026-09-04
NCT06124157A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adoleprednisone intensolNational Cancer Institute (NCI)Recruiting2026-09-04
NCT06124157A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, AdolethioguanineNational Cancer Institute (NCI)Recruiting2026-09-04
NCT06124157A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolethioguanine hydrateNational Cancer Institute (NCI)Recruiting2026-09-04
NCT06124157A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, AdolevincristineNational Cancer Institute (NCI)Recruiting2026-09-04
NCT06132113DAREON™-7: A Study to Test How Well Different Doses of BI 764532 in Addition to Chemotherapy Are Tolerated by People WitetoposideBoehringer IngelheimActive Not Recruiting2026-09-04
NCT06203600Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE TrialpaclitaxelNational Cancer Institute (NCI)Recruiting2026-09-04
NCT06236438Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With BcisplatinAbbVieRecruiting2026-09-04
NCT06236438Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With BpembrolizumabAbbVieRecruiting2026-09-04
NCT07479797Study Evaluating the Efficacy of KITE-753 Versus Axicabtagene Ciloleucel in Participants With Relapsed or Refractory LarfludarabineKite, A Gilead CompanyRecruiting2026-09-04
NCT07509034Autologous B7-H3 Chimeric Antigen Receptor T Cells in Previously Treated Extensive-Stage Small Cell Lung Cancer With ReccyclophosphamideNational Cancer Institute (NCI)Not Yet Recruiting2026-09-04
NCT07512596Study on the Safety and Efficacy of Polymyxin E2 Methanesulfonate for Injection in the Treatment of Hospital-Acquired Bacolistimethate sodium for injectionChia Tai Tianqing Pharmaceutical Group Co., Ltd.Recruiting2026-09-04
NCT07512596Study on the Safety and Efficacy of Polymyxin E2 Methanesulfonate for Injection in the Treatment of Hospital-Acquired Bameropenem for injectionChia Tai Tianqing Pharmaceutical Group Co., Ltd.Recruiting2026-09-04
NCT07524530Stem Cell Transplantation for Participants With Germline RUNX1 Associated Blood CancersfludarabineNational Cancer Institute (NCI)Not Yet Recruiting2026-09-04
NCT07524530Stem Cell Transplantation for Participants With Germline RUNX1 Associated Blood Cancersmycophenolate mofetilNational Cancer Institute (NCI)Not Yet Recruiting2026-09-04
NCT07549490Human Experimental Models of Pain (HEMP)naproxenNational Center for Complementary and Integrative Health (NCNot Yet Recruiting2026-09-04
NCT07549490Human Experimental Models of Pain (HEMP)pregabalinNational Center for Complementary and Integrative Health (NCNot Yet Recruiting2026-09-04
NCT07604571Study of IEV407 as Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast CancerletrozoleNovartis PharmaceuticalsRecruiting2026-09-04
NCT07612839Intravenous Lidocaine for Postoperative Fatigue After Laparoscopic TAPP Inguinal Hernia RepairlidocaineHakan EmirkadıNot Yet Recruiting2026-09-04
NCT07613723A Study to Test the Safety, Tolerability and Effect of ZI-MA4-1 for Patients With Locally Advanced or Metastatic Solid MfludarabineZelluna Immunotherapy ASRecruiting2026-09-04
NCT07638527Time to First Rescue Antiemetic With Ondansetron Plus Metoclopramide Versus Dexamethasone Plus Metoclopramide for PONV PdexamethasoneFaisalabad Medical UniversityRecruiting2026-09-04
NCT07803653IL-18 Armored STEAP1 CAR T Cells for the Treatment of Metastatic Castration Resistant Prostate CancercyclophosphamideFred Hutchinson Cancer CenterNot Yet Recruiting2026-09-04
NCT07803653IL-18 Armored STEAP1 CAR T Cells for the Treatment of Metastatic Castration Resistant Prostate Cancercyclophosphamide monohydrateFred Hutchinson Cancer CenterNot Yet Recruiting2026-09-04
NCT07803783A Study to Compare the Efficacy and Safety of YL201 With Standard Chemotherapy in Patients With Metastatic Pancreatic CaleucovorinMediLink Therapeutics (Suzhou) Co., Ltd.Not Yet Recruiting2026-09-04
NCT07804186Study of Adjuvant Darovasertib and Crizotinib in Participants With Primary Non-metastatic Uveal MelanomacrizotinibIDEAYA BiosciencesRecruiting2026-09-04
NCT07613723A Study to Test the Safety, Tolerability and Effect of ZI-MA4-1 for Patients With Locally Advanced or Metastatic Solid McyclophosphamideZelluna Immunotherapy ASRecruiting2026-09-04
NCT02208375mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and OvariancapivasertibM.D. Anderson Cancer CenterActive Not Recruiting2026-09-04
NCT02559778Pediatric Precision Laboratory Advanced Neuroblastoma TherapyceritinibGiselle ShollerRecruiting2026-09-04
NCT02559778Pediatric Precision Laboratory Advanced Neuroblastoma TherapydasatinibGiselle ShollerRecruiting2026-09-04
NCT04013854Adjuvant Treatment Determined By Pathological Response To Neoadjvuant NivolumabipilimumabAbramson Cancer Center at Penn MedicineActive Not Recruiting2026-09-04
NCT04013854Adjuvant Treatment Determined By Pathological Response To Neoadjvuant NivolumabnivolumabAbramson Cancer Center at Penn MedicineActive Not Recruiting2026-09-04
NCT04340141Testing the Use of the Usual Chemotherapy Before and After Surgery for Removable Pancreatic Canceririnotecan hydrochlorideAlliance for Clinical Trials in OncologyActive Not Recruiting2026-09-04
NCT04340141Testing the Use of the Usual Chemotherapy Before and After Surgery for Removable Pancreatic CanceroxaliplatinAlliance for Clinical Trials in OncologyActive Not Recruiting2026-09-04
NCT04589845Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform StudyalectinibHoffmann-La RocheActive Not Recruiting2026-09-04
NCT04589845Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform StudyatezolizumabHoffmann-La RocheActive Not Recruiting2026-09-04
NCT04589845Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform StudyinavolisibHoffmann-La RocheActive Not Recruiting2026-09-04
NCT04589845Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Studytrastuzumab emtansineHoffmann-La RocheActive Not Recruiting2026-09-04
NCT04680052A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus LerituximabIncyte CorporationActive Not Recruiting2026-09-04
NCT04680052A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus LetafasitamabIncyte CorporationActive Not Recruiting2026-09-04
NCT04746235Venetoclax and ASTX727 for the Treatment of Relapsed, Refractory, or Newly Diagnosed Acute Myeloid LeukemiavenetoclaxM.D. Anderson Cancer CenterActive Not Recruiting2026-09-04
NCT04822181Research Study on Whether Semaglutide Works in People With Non-alcoholic Steatohepatitis (NASH)semaglutideNovo Nordisk A/SActive Not Recruiting2026-09-04
NCT05198830Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or CarbocisplatinNational Cancer Institute (NCI)Active Not Recruiting2026-09-04
NCT05198830Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or CarbopemetrexedNational Cancer Institute (NCI)Active Not Recruiting2026-09-04
NCT05675410A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumabbrentuximab vedotinNational Cancer Institute (NCI)Recruiting2026-09-04
NCT05675410A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and NivolumabcyclophosphamideNational Cancer Institute (NCI)Recruiting2026-09-04
NCT05675410A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumabdacarbazine - dticNational Cancer Institute (NCI)Recruiting2026-09-04
NCT05675410A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumabdoxorubicin hydrochlorideNational Cancer Institute (NCI)Recruiting2026-09-04
NCT05675410A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumabetoposide phosphateNational Cancer Institute (NCI)Recruiting2026-09-04
NCT05675410A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and NivolumabprednisoloneNational Cancer Institute (NCI)Recruiting2026-09-04
NCT05675410A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumabvincristine sulfateNational Cancer Institute (NCI)Recruiting2026-09-04
NCT05713799Trial of the Combination of Alpha-Lipoic Acid and Mirabegron in Women and in Men With ObesitymirabegronNational Institute of Diabetes and Digestive and Kidney DiseNot Yet Recruiting2026-09-04
NCT05751512A Study to Evaluate MRG003 vs Cetuximab/Methotrexate in in the Treatment of Patients With RM-SCCHNmethotrexate injectionLepu Biopharma Co., Ltd.Recruiting2026-09-04
NCT05841056Short Term Anti-aRrhythmic Therapy for Post-Operative AF in Cardiac Surgery Patients Pilot Trialamiodarone hydrochloride 200 mgPopulation Health Research InstituteRecruiting2026-09-04
NCT06043323A Phase II Study of Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor (CAR) Tcell Therapy, in Combination axicabtagene ciloleucelM.D. Anderson Cancer CenterRecruiting2026-09-04
NCT06384222Hyperpolarized (HP) 13C Pyruvate Magnetic Resonance Imaging (MRI) for Response Monitoring to Neoadjuvant AbirateroneabirateroneIvan de Kouchkovsky, MDActive Not Recruiting2026-09-04

Request a quote

Nexara Health is a Health Canada–licensed pharmaceutical wholesaler (DEL #3-002896) based in Winnipeg, Manitoba, supplying hospitals, pharmacies, clinics, CROs, and trial sponsors across Canada. Send us the product, strength, presentation, and quantity for clinical trial comparator supply and we will come back with availability, source market, lead time, and landed cost — usually within 24 hours.

Request a sourcing quote or call +1-431-588-9055.

Related pages